Beijing Tong Ren Tang Chinese Medicine Company Limited
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) Financial Performance & Income Statement Overview
Explore the financials of Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF), including yearly and quarterly data on income, cash flow, and balance sheets.
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) Income Statement & Financial Overview
Review Beijing Tong Ren Tang Chinese Medicine Company Limited BJTRF income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $473.56M | $473.56M | $42.55M | $42.46M |
| Cost of Revenue | $166.78M | $166.78M | $13.62M | $13.59M |
| Gross Profit | $306.78M | $306.78M | $28.93M | $28.87M |
| Gross Profit Ratio | $0.65 | $0.65 | $0.68 | $0.68 |
| R&D Expenses | $4.56M | $4.56M | $0.00 | $0.00 |
| SG&A Expenses | $148.58M | $148.58M | $12.60M | $12.57M |
| Operating Expenses | $147.76M | $147.76M | $12.35M | $12.32M |
| Total Costs & Expenses | $314.54M | $314.54M | $25.97M | $25.92M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $4.17M | $4.65M | $595785.00 | $594532.00 |
| EBITDA | $161.76M | $162.24M | $17.17M | $17.14M |
| EBITDA Ratio | $0.34 | $0.34 | $0.40 | $0.40 |
| Operating Income | $159.02M | $159.02M | $16.58M | $16.54M |
| Operating Income Ratio | $0.34 | $0.34 | $0.39 | $0.39 |
| Other Income/Expenses (Net) | $14.04M | $14.04M | $1.59M | $1.58M |
| Income Before Tax | $173.07M | $173.07M | $18.16M | $18.12M |
| Income Before Tax Ratio | $0.37 | $0.37 | $0.43 | $0.43 |
| Income Tax Expense | $28.65M | $28.65M | $2.77M | $2.77M |
| Net Income | $140.25M | $140.25M | $14.07M | $14.04M |
| Net Income Ratio | $0.30 | $0.30 | $0.33 | $0.33 |
| EPS | $0.17 | $0.17 | $0.02 | $0.02 |
| Diluted EPS | $0.17 | $0.17 | $0.02 | $0.02 |
| Weighted Avg Shares Outstanding | $837.10M | $837.10M | $837.11M | $837.11M |
| Weighted Avg Shares Outstanding (Diluted) | $837.10M | $837.10M | $837.10M | $837.10M |
Over the last four quarters, Beijing Tong Ren Tang Chinese Medicine Company Limited's revenue moved from $42.46M in Q1 2024 to $473.56M in Q4 2024. Operating income in Q4 2024 was $159.02M, with a strong operating margin of 34%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Beijing Tong Ren Tang Chinese Medicine Company Limited remained robust at $161.76M, reflecting operational efficiency. Net income rose to $140.25M, with an EPS of $0.17. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan